Radiomics Analysis of 3D Dose Distributions to Predict Toxicity of Radiotherapy for Cervical Cancer.

NTCP cervical cancer radiomics radiotherapy toxicity

Journal

Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269

Informations de publication

Date de publication:
11 May 2021
Historique:
received: 26 03 2021
revised: 08 05 2021
accepted: 10 05 2021
entrez: 2 6 2021
pubmed: 3 6 2021
medline: 3 6 2021
Statut: epublish

Résumé

Standard treatment for locally advanced cervical cancer (LACC) is chemoradiotherapy followed by brachytherapy. Despite radiation therapy advances, the toxicity rate remains significant. In this study, we compared the prediction of toxicity events after radiotherapy for locally advanced cervical cancer (LACC), based on either dose-volume histogram (DVH) parameters or the use of a radiomics approach applied to dose maps at the voxel level. Toxicity scores using the Common Terminology Criteria for Adverse Events (CTCAE v4), spatial dose distributions, and usual clinical predictors for the toxicity of 102 patients treated with chemoradiotherapy followed by brachytherapy for LACC were used in this study. In addition to usual DVH parameters, 91 radiomic features were extracted from rectum, bladder and vaginal 3D dose distributions, after discretization into a fixed bin width of 1 Gy. They were evaluated for predictive modelling of rectal, genitourinary (GU) and vaginal toxicities (grade ≥ 2). Logistic Normal Tissue Complication Probability (NTCP) models were derived using clinical parameters only or combinations of clinical, DVH and radiomics. For rectal acute/late toxicities, the area under the curve (AUC) using clinical parameters was 0.53/0.65, which increased to 0.66/0.63, and 0.76/0.87, with the addition of DVH or radiomics parameters, respectively. For GU acute/late toxicities, the AUC increased from 0.55/0.56 (clinical only) to 0.84/0.90 (+DVH) and 0.83/0.96 (clinical + DVH + radiomics). For vaginal acute/late toxicities, the AUC increased from 0.51/0.57 (clinical only) to 0.58/0.72 (+DVH) and 0.82/0.89 (clinical + DVH + radiomics). The predictive performance of NTCP models based on radiomics features was higher than the commonly used clinical and DVH parameters. Dosimetric radiomics analysis is a promising tool for NTCP modelling in radiotherapy.

Identifiants

pubmed: 34064918
pii: jpm11050398
doi: 10.3390/jpm11050398
pmc: PMC8151048
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Radiother Oncol. 2020 Feb;143:1-11
pubmed: 31564555
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S3-9
pubmed: 20171515
Radiother Oncol. 2016 Sep;120(3):447-454
pubmed: 27157510
Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1088-98
pubmed: 26876955
Clin Lung Cancer. 2017 Nov;18(6):e425-e431
pubmed: 28623121
Radiology. 2020 May;295(2):328-338
pubmed: 32154773
Phys Med Biol. 2016 Jul 7;61(13):R150-66
pubmed: 27269645
Br J Radiol. 2017 Feb;90(1070):20160665
pubmed: 27936886
J Clin Epidemiol. 2001 Aug;54(8):774-81
pubmed: 11470385
J Nucl Med. 2018 Feb;59(2):189-193
pubmed: 29175982
Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):1-4
pubmed: 29254765
Eur J Nucl Med Mol Imaging. 2019 Apr;46(4):864-877
pubmed: 30535746
Radiat Oncol. 2018 Jul 6;13(1):125
pubmed: 29980214
Radiat Oncol. 2018 Sep 14;13(1):177
pubmed: 30217165
Br J Cancer. 2011 Sep 6;105(6):737-45
pubmed: 21847122
Radiother Oncol. 2012 Nov;105(2):266-8
pubmed: 23157980
Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):151-165
pubmed: 27271051
Med Phys. 2012 Oct;39(10):6332-8
pubmed: 23039669
Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):1048-56
pubmed: 25670540
Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):895-902
pubmed: 30940530
Radiother Oncol. 2018 Dec;129(3):548-553
pubmed: 30177372
Brachytherapy. 2018 Nov - Dec;17(6):922-928
pubmed: 30061056
Ann Intern Med. 2015 Jan 6;162(1):W1-73
pubmed: 25560730
Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1099-105
pubmed: 26883564
Phys Med Biol. 2015 Jul 21;60(14):5471-96
pubmed: 26119045
Phys Med Biol. 2017 May 21;62(10):4118-4139
pubmed: 28445167
Cancer Med. 2016 Mar;5(3):434-41
pubmed: 26806114
Med Phys. 2018 Nov;45(11):5317-5324
pubmed: 30133809
Nat Commun. 2014 Jun 03;5:4006
pubmed: 24892406
Cancer Radiother. 2016 Jul;20(5):370-6
pubmed: 27368915
Tomography. 2016 Dec;2(4):430-437
pubmed: 28149958
Radiother Oncol. 2017 Feb;122(2):185-191
pubmed: 27459902
J Nucl Med. 2017 Mar;58(3):365-366
pubmed: 27811126
Eur J Nucl Med Mol Imaging. 2019 Dec;46(13):2638-2655
pubmed: 31240330
Radiother Oncol. 2016 Aug;120(2):258-66
pubmed: 27296412
Radiother Oncol. 2004 Jun;71(3):333-7
pubmed: 15172150
JAMA Oncol. 2018 Jul 12;4(7):e173776
pubmed: 29145543
Oncotarget. 2017 Jun 27;8(26):43169-43179
pubmed: 28574816
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Clin Transl Radiat Oncol. 2018 Jan 11;9:48-60
pubmed: 29594251
Int J Radiat Oncol Biol Phys. 2013 Nov 1;87(3):542-8
pubmed: 24074927
Cancer. 2018 Nov 15;124(22):4383-4392
pubmed: 30329160
Front Oncol. 2018 Mar 05;8:35
pubmed: 29556480
Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):348-55
pubmed: 20472347
Brachytherapy. 2017 Jan - Feb;16(1):116-125
pubmed: 27876378

Auteurs

François Lucia (F)

Radiation Oncology Department, University Hospital, CHRU Morvan, 2 avenue Foch, CEDEX, 29609 Brest, France.
LaTIM, INSERM, UMR 1101, Univ Brest, 29200 Brest, France.

Vincent Bourbonne (V)

Radiation Oncology Department, University Hospital, CHRU Morvan, 2 avenue Foch, CEDEX, 29609 Brest, France.
LaTIM, INSERM, UMR 1101, Univ Brest, 29200 Brest, France.

Dimitris Visvikis (D)

LaTIM, INSERM, UMR 1101, Univ Brest, 29200 Brest, France.

Omar Miranda (O)

Radiation Oncology Department, University Hospital, CHRU Morvan, 2 avenue Foch, CEDEX, 29609 Brest, France.
Radiation Oncology Department, Cornouaille Hospital, 29000 Quimper, France.

Dorothy M Gujral (DM)

Clinical Oncology Department, Imperial College Healthcare NHS Trust, Charing Cross Hospital, Hammersmith, London W6 8RF, UK.
Department of Cancer and Surgery, Imperial College London, London SW6 4NE, UK.

Dominique Gouders (D)

Radiation Oncology Department, Cornouaille Hospital, 29000 Quimper, France.

Gurvan Dissaux (G)

Radiation Oncology Department, University Hospital, CHRU Morvan, 2 avenue Foch, CEDEX, 29609 Brest, France.
LaTIM, INSERM, UMR 1101, Univ Brest, 29200 Brest, France.

Olivier Pradier (O)

Radiation Oncology Department, University Hospital, CHRU Morvan, 2 avenue Foch, CEDEX, 29609 Brest, France.
LaTIM, INSERM, UMR 1101, Univ Brest, 29200 Brest, France.

Florent Tixier (F)

LaTIM, INSERM, UMR 1101, Univ Brest, 29200 Brest, France.

Vincent Jaouen (V)

LaTIM, INSERM, UMR 1101, Univ Brest, 29200 Brest, France.

Julien Bert (J)

LaTIM, INSERM, UMR 1101, Univ Brest, 29200 Brest, France.

Mathieu Hatt (M)

LaTIM, INSERM, UMR 1101, Univ Brest, 29200 Brest, France.

Ulrike Schick (U)

Radiation Oncology Department, University Hospital, CHRU Morvan, 2 avenue Foch, CEDEX, 29609 Brest, France.
LaTIM, INSERM, UMR 1101, Univ Brest, 29200 Brest, France.

Classifications MeSH